MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway.

Authors :: De Mello RA
Aguiar PN
Tadokoro H
Farias-Vieira TM
Castelo-Branco P
de Lima Lopes G
Pozza DH
Source :: Journal of thoracic disease [J Thorac Dis] 2018 Jun; Vol. 10 (Suppl 17), pp. S2076-S2078.
Publication Year :: 2018
Abstract: Competing Interests: Conflicts of Interest: RA de Mello is advisory board consultant for Zodiac, MSD, Pfizer; Speaker fee from Astrazenenca, Novartis. Honoraria from National Medical Research Council, Singapore, and National Science Centre, Krakow, Poland. The other authors have no conflicts of interest to declare.

Full Text Access

Tools